Sentences with phrase «developing immune therapies»
Our mission at iTeos is to discover and develop immune therapies to benefit cancer patients.
http://www.iteostherapeutics.com/ Not exact matches
CAR - T cell therapy is a form of immunotherapy, a rapidly developing cancer treatment that uses patients» own immune cells to attack tumors.
Santa Monica, California - based Kite is developing chimeric antigen receptor T - cell therapy, known as a CAR T, which harnesses the body's own immune cells to recognize and attack malignant cells.
More and more, Sweeney says, the immune system is proving to be the most difficult hurdle in developing gene therapy for humans.
In addition to formulating diagnostic strategies for cancer immunotherapy agents, her team is focused on developing a deep understanding of tumor immune biology as well as mechanisms associated with immune response and immune escape in cancer patients, with the intent of generating rational strategies for the creation of combination therapies.
Researchers are developing many different versions of CAR - T cell therapies, but the basic premise is the same: Doctors remove a patient's T cells (immune system cells that attack invaders) from a blood sample and genetically modify them to produce artificial proteins on their surfaces.
Researchers at The University of Texas MD Anderson Cancer Center developed a novel chimeric mouse model to test the combination therapy using immune checkpoint blockades with therapies targeting myeloid - derived suppressor cells (MDSCs).
«It is expected that this study will lay the foundation for developing a new class of potent and effective cancer therapies and the development of reagents targeting epigenetic events in immune - mediated diseases as well as other epigenetically - influenced diseases,» said Alani, who also is chief of dermatology at Boston Medical Center.
«The control of immune cell entry into the joint represents a major point at which new therapies could be developed to reduce the symptoms of inflammatory arthritis,» says Luster, who is the Harrison Professor of Medicine at Harvard Medical School.
This knowledge could help develop customized therapies, like training the body's immune system to respond to certain proteins found in foods.
In June 2002, for example, a young girl treated with a new genetic therapy developed at the San Raffaele Hospital in Milan was cured of severe immune deficiency syndrome.
One 18 - year - old patient died in a trial in 1999, and a promising French trial of therapy for inherited immune deficiency was suspended last year after three patients developed leukemia, leading The Wall Street Journal to proclaim that «the field seems cursed.»
Kole Roybal is the 2018 grand prize winner of the inaugural Sartorius & Science Prize for Regenerative Medicine & Cell Therapy, for developing a new class of T cell immunotherapies that can be fine - tuned to better help the immune system recognize cancer and initiate precise therapeutic action against the disease.
She is currently at Rockefeller University, where she is studying the interactions between immune cells and stem cells in an effort to develop stem cell - based therapies for inflammatory disorders.
«Understanding how the invading Ebola virus impacts the host's immune system is a very important step in developing targeted therapies for Ebola virus disease,» said Bukreyev.
«Antiviral therapy prolongs survival in immune tolerant hepatitis B patients: Nucleos (t) ide analogue treatment reduces risk of developing liver cancer and liver cirrhosis among immune tolerant patients.»
And while new therapies have been effective in releasing the immune system's restraints to unleash the body's own cancer - fighting powers, they only work in about half of melanoma patients and often lose their potency as the cancer develops resistance.
She is currently at Rockefeller University, where she is studying the interactions between immune cells and stem cells in an effort to develop stem cell — based therapies for inflammatory disorders.
As a result, there is now a push to develop combination therapies, in which different but complementary treatments are used to boost the immune response.
But if the immune system is involved in the new - found problems, it provides additional impetus to develop «personalised» therapies, in which neurons are grown from a patient's own cells, and so should be less likely to provoke an immune reaction.
The announcement last month that a fifth child who received gene therapy for an immune system disease has developed leukemia was the latest blow to the field of gene therapy.
New research into Amyotrophic Lateral Sclerosis (ALS)-- also known as motor neuron disease — shows that specific immune cells may help slow progression of the disease, an important step towards developing new therapies to treat patients.
Other research at U-M is developing new options for treating brain cancer through immunotherapy — harnessing the immune system to attack cancer cells once an injection of a particular gene therapy is delivered into the brain tumor.
Patients with severe combined immunodeficiency (SCID) show unprecedented immune system recovery after receiving gene therapy developed at St. Jude.
GigaGen is a biopharmaceutical company that develops novel antibody therapies derived from immune repertoires.
In theory, the developing fetus with an immature immune system should be a prime target for successful transplantation, since the risk of graft rejection is low and the need for long - term immunosuppressive therapy may be avoided.
This will fast - track new immune - modulating therapies for cancer patients by discovering and developing small molecule product candidates against immuno - oncology targets.
My personal goal is to deeply understand how the immune system recognizes cancers and eliminates it, and then to use that knowledge to develop increasingly specific and powerful therapies to control cancer.
The long - term vision is to apply these technologies to other genetic diseases, such as sickle cell disease, and to explore applications in developing effective immune therapies for cancer.
Since lentiviral vectors can deliver a large amount of DNA (~ 8 kb) with a relatively low immune response, it should come as no surprise that researchers are interested in developing these vectors for gene therapy.
We're also developing cellular therapies, which improve the canker - killing activity of powerful immune cells called NK cells and T cells, rather than using drugs to treat the cancer directly.
«We are currently working to identify the relationship between the circadian clock, metabolism and the immune system, so that one day we could develop therapies to treat diseases influenced by circadian clock disruption — including not only obesity and diabetes, but also potentially multiple sclerosis and even Alzheimer's disease.»
The results of her project will help scientists develop novel therapies to target the regulatory proteins that cause CD47 overproduction in leukemia and other cancer stem cells, with the goal of restoring immunosurveillance and enabling the immune system to recognize and destroy these aberrant cancer cells.
In the next year, members of the Dream Team will continue to study the tumor microenvironment before and after checkpoint blockade, to develop algorithms to identify and predict the best antigens on cancer cells that can be used for cancer immunotherapies, to analyze tumor tissues and blood for biomarkers that will help in selecting patients who will benefit, and identifying the best approaches to increase the strength of immune cells for adoptive cell therapy.
With this approach, scientists can develop cell - based therapies that use engineered cells from the immune system as the «drug».
The ITN develops and conducts clinical studies of immune tolerance therapies — highly targeted treatments designed to prevent disease - causing immune responses, without compromising the natural protective properties of the immune system.
The focus of Memorial Sloan Kettering's Ludwig Center for Cancer Immunotherapy is to explore and develop innovative therapies that act by stimulating or strengthening the immune system's inherent ability to fight cancer.
Sophisticated cell targeting systems such as the gene therapy approach developed for senescent cell clearance by Oisin Biotechnologies could also be turned to stem cell or immune cell destruction, given suitable markers of cell chemistry.
Robert D. Schreiber, Ph.D., an associate director of CRI's Scientific Advisory Council based at Washington University School of Medicine in Saint Louis, Missouri, developed a new model of breast cancer that more closely resembles the progression of hormone receptor - positive disease in humans, overcoming a major obstacle in the study of breast cancer and the development of new immune - based therapies for the disease.
In a paper published online Aug. 31, by Nature Medicine, researchers report that using a monoclonal antibody called anti-CD47, which blocks the «don't - eat - me» signal on malignant cells, to treat mice with an intact immune system provides a much more lifelike way to study and develop an immune - based cancer therapy.
I decided that my new lab would work on understanding the T - cell response to HIV and why these cells fail to control the infection, with an eye towards developing immune - based therapy.
The major benefit of using iPS cells to treat AMD is that developing a patient specific therapy may help to eliminate the problems associated with immune rejection.
Co-engrafting mice with human tumors that retain the same characteristics and human immune cells, is a new platform to study the relationship between the human immune system and tumors and develop immuno - oncology - based cancer therapies.
Improving Stem Cell Treatment Success Researchers will manipulate the expression of immune markers on stem cells to develop safer and more effective therapies for horses with musculoskeletal injuries.
Researchers will manipulate the expression of immune markers on stem cells to develop safer and more effective therapies for horses with musculoskeletal injuries.